Life Tech Rips Promega Bid To Rethink US Damages In IP Row

Law360, New York (January 30, 2018, 9:52 PM EST) -- Life Technologies Corp. on Monday urged the Federal Circuit to uphold its finding that Promega Corp. doesn't deserve U.S.-specific damages in patent litigation over genetic-testing kits, despite pleas from Promega for a rehearing before the full court.

In November, the circuit court found that Promega waived its right to ask for damages just from U.S. sales when it insisted on a worldwide "all-or-nothing damages strategy." While Promega denies ever taking such a stance, Life Tech claims Promega was singularly focused on a larger damages pool and didn't introduce evidence to separate domestic damages.

"There is no reason to create the perverse...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!